The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
2016; Nature Portfolio; Volume: 538; Issue: 7626 Linguagem: Inglês
10.1038/nature19830
ISSN1476-4687
AutoresAndrás Kotschy, Zoltán Szlávik, James B. Murray, James Davidson, Ana Leticia Maragno, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Gemma L. Kelly, Jianan Gong, Donia Moujalled, Alain Bruno, Márton Csékei, Attila Paczal, Z. Szabó, Szabolcs Sipos, Gábor Radics, Ágnes Proszenyák, Balázs Bálint, Levente Ondi, Gábor Blasko, Alan Robertson, A.E. Surgenor, P. Dokurno, I‐Jen Chen, Natalia Matassova, Julia Smith, C. Pedder, Christopher Graham, Aurélie Studeny, Gaëlle Lysiak-Auvity, Anne-Marie Girard, Fabienne Gravé, David Segal, Chris Riffkin, Giovanna Pomilio, Laura C.A. Galbraith, Brandon J. Aubrey, Margs S. Brennan, Marco J. Herold, Catherine Chang, Ghislaine Guasconi, Nicolas Cauquil, Fabien Melchiore, Nolwen Guigal-Stéphan, Brian P. Lockhart, Frédéric Colland, John A. Hickman, Andrew W. Roberts, David C.S. Huang, Andrew H. Wei, Andreas Strasser, Guillaume Lessène, Olivier Geneste,
Tópico(s)Cancer-related Molecular Pathways
Referência(s)